Daijo Inaguma, Fumihiko Koiwa, Masanori Tokumoto, Masafumi Fukagawa, Shinji Yoneda, Hisami Yasuzawa, Kenji Asano, Keiko Hagita, Yosuke Inagaki, Daisuke Honda, Tadao Akizawa
BACKGROUND: Upacicalcet is a novel small-molecule calcimimetic agent developed for intravenous injection. Here, we evaluated the long-term efficacy and safety of upacicalcet treatment via intraindividual dose adjustment in haemodialysis patients with secondary hyperparathyroidism (SHPT). METHODS: A phase 2, multicentre, open-label, single-arm study was conducted. Upacicalcet was administered for 52 weeks; the starting dose was 50 μg thrice a week, and then adjusted to 25, 50, 100, 150, 200, 250, or 300 μg, according to the dose-adjustment method set in the protocol...
December 2023: Clinical Kidney Journal